MOS testbed for the characterization of targeted alpha therapy pharmaceuticals

From National Research Council Canada

DOIResolve DOI:
AuthorSearch for: 1; Search for: ; Search for: ; Search for:
  1. National Research Council of Canada. Information and Communication Technologies
FormatText, Article
Subjectpharmaceutical development; Metal-Oxide-Semiconductor; MOS; Radioimmunotherapy; RIT; Targeted Alpha Therapy; TAT; Targeted Radionuclide Therapy; TRT; aptamer; DNA; chelator characterization; DOTA
Publication date
Peer reviewedYes
NPARC number23001036
Export citationExport as RIS
Report a correctionReport a correction (opens in a new tab)
Record identifier7445addb-c992-4ef5-9a3a-94762dbba3b9
Record created2016-12-02
Record modified2020-04-22
Date modified: